Abbott Abbvie Acpeth Actelion Pharmaceuticals Air Liquide

Total Page：16

File Type：pdf, Size：1020Kb

Abbott Abbvie Acpeth Actelion Pharmaceuticals Air Liquide

Abbott Focus Care Pharmaceuticals Roche Abbvie Fresenius Kabi Roche Diabetes Care Acpeth Fresenius Medical Care Sandoz Actelion Pharmaceuticals Galderma Sanofi Air Liquide Medical GDM Sanquin Plasma Products Alcon GE Healthcare Santen Alfasigma Gedeon Richter Santhera ALK Abello Genzyme Sarepta Allergan Gilead Sciences Servier Allwecare Medical Glaxosmithkline Shire Almirall Goodlife Fertility Siemens Healthcare Amgen Goodlife Healthcare Skylinedx Arthrex Grünenthal Smith & Nephew Astellas Pharma Guerbet Sobi (Swedish Orphan Biovitrum) Astrazeneca Horus Pharma Springmedical Atricure Intercept Pharma Stryker Audmet Ipsen Farmaceutica Sunovion Pharmaceuticals Avexis Janssen -Cilag Takeda B.Braun Medical Jazz Pharmaceuticals Teleflex Medical Bausch&Lomb OPS Johnson & Johnson Medical Terumo Baxter Kyowa Kirin Pharma Teva Bayer Laevo The Binding Site Bayer Animal Health Lamepro The Corpus Becton Dickinson Laservision Instruments Théa Pharma Beldico Leo Pharma Therabel Pharma Biogen Link Tillotts Pharma Bio-Rad Laboratories Livanova Titus Health Care Biotronik Lohmann & Rauscher UCB Pharma Bioventus Lundbeck Varian Medical Systems Boehringer Ingelheim Manfred Sauer Vertex Pharmaceuticals Boehringer Ingelheim Animal Health Maquet Vifor Pharma Boston Scientific Masimo W.L. Gore & Associates Bristol-Myers Squibb Meda Pharma Will Pharma Canon Medical Systems Medice Zambon Cardinal Health Medtronic Bakken Research Center Zimmer Biomet Celgene Medtronic Trading Zoetis Animal Health Cepheid Menarini Ceva Sante Animale Merck Chiesi Pharmaceuticals Merit Medical Cook Medical Merz Pharma CR Bard Microport CRM Cresco Pharma Mölnlycke Health Care CSL Behring MSD Curium MSD Animal Health D&M Mundipharma Pharmaceuticals D.O.R.C. Mylan Daiichi Sankyo Mylan Healthcare Dentsply Sirona Nobel Biocare Depuy Synthes Nordic Pharma Dopharma Healthy Livestock Norgine Dr Falk Pharma Novartis Pharma Duo-Med Novo Nordisk Edwards Lifesciences Olympus Eisai Otsuka Pharmaceuticals Eli Lilly Pfizer Eli Lilly Animal Health Philips Electronics Eurocept Pharmaceuticals Pierre fabre Exatech Pierre fabre sante Ferring Pro Care.

Copy Link

Recommended publications

Benadryl Allergy Relief Plus Decongestant Capsules
Distance between cutted line/middel of the spot = 51.6 mm spot = 12 x 2 centered in the margin of 14 mm le f 14 mm GB Benadryl Allergy Relief Plus Decon Caps 12s PIL MAH Update CRD 6738 t margin 23.06.2021 English 402428175_r0 N/A 1 Brochure/Leaet/Insert 145 x 250 mm Capsules are a medicine which are used to blood pressure). 364350C IM_Val-de-Reuil_Upper Normandy_France relieve the symptoms of hay fever and similar ■ If you have glaucoma (increased pressure allergic conditions. The capsules contain in the eye). CTE LITE 364350B Westrock Saint Pierre des Corps pseudoephedrine hydrochloride, which is a ■ If you have an overactive thyroid gland. 845 Oset Printing decongestant that relieves nasal and sinus ■ If you have severe kidney problems. 7996903 PAPER congestion and acrivastine which is an ■ If you are taking, or have taken in the last EMEA_2021_00024796_003 PC-0002778 antihistamine that helps relieve allergy two weeks, drugs for depression known symptoms such as sneezing, runny nose and as Monoamine Oxidase Inhibitors CAPSULES watery eyes. (MAOIs) or Reverse Inhibitors of Acrivastine 8mg & Pseudoephedrine 60mg Monoamine Oxidase 2 Before taking this (RIMAs). ■ This medicine is used to relieve the symptoms ■ If you are taking any cough or of hay fever and similar allergic conditions. cold medicines. PANTONE PANTONE medicine 356 C 287 C ■ This medicine is for use by adults and If any of these apply to you, get advice from children aged 12 - 65 years. This medicine is suitable for most adults under LITHO OFFSET LITHO OFFSET 65 years old and children aged 12 years and a doctor or pharmacist without taking ■ Do not take this medicine: REPRESENTATION: Colours represented with a diagonal line have been modiﬁed to aid PDF approval.
[Show full text]
Snippet Roundup: CETP Kaput and Biogen Buys Into Amyloid
October 27, 2017 Snippet roundup: CETP kaput and Biogen buys into amyloid Edwin Elmhirst Welcome to your weekly roundup of EP Vantage’s snippets – short takes on smaller news items. This week, October 23 to 27, 2017, we had thoughts on the following: Amgen puts another CETP out of its misery; Stryker buys Vexim without waiting for US approval; How much is aducanumab worth? At least $8bn, Biogen reckons; Alcon delay puts dampener on Novartis; Soliris sitting pretty with complementary new indication; Smith & Nephew acquires, but divestments could follow; Global Blood drops IPF programme. These snippets were previously published daily via twitter. Amgen puts another CETP out of its misery October 26, 2017 If the once-promising CETP drug class lives on, it might only be in a rather restricted group of heart disease patients with a very specific mutation. Amgen became the last big biopharma group to cancel work on a drug in the HDL-raising class when it announced plans to seek a partner for AMG 899, following the lead of Merck & Co, which recently terminated its work with anacetrapib after disappointing results in the Reveal trial. Although big pharma groups obviously believe that it is unlikely for a CETP inhibitor to succeed commercially, it is not out of the realm of possibility that a partner could emerge for AMG 899 – Roche licensed its project, dalcetrapib, to the Canadian group Dalcor Pharmaceuticals, which has been researching its use in a genetic subtype, patients with an AA polymorphism at the rs1967309 location in the ADCY9 gene. Amgen will write off the $300m it paid for AMG 899’s originator, Dezima Pharma, in 2015, which at the time was seen as a cheap bet on the CETP sector.
[Show full text]
From the Academy
FROM THE ACADEMY Joint American Academy of DermatologyeNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy Craig A. Elmets, MD (Co-Chair),a HenryW.Lim,MD,b Benjamin Stoff, MD, MA,c Cody Connor, MD,a Kelly M. Cordoro, MD,d Mark Lebwohl, MD,e AprilW.Armstrong,MD,MPH,f Dawn M. R. Davis, MD,g Boni E. Elewski, MD,a Joel M. Gelfand, MD, MSCE,h Kenneth B. Gordon, MD,i AliceB.Gottlieb,MD,PhD,j Daniel H. Kaplan, MD, PhD,k Arthur Kavanaugh, MD,l Matthew Kiselica, BA/BS,m Dario Kivelevitch, MD,n Neil J. Korman, MD, PhD,o Daniela Kroshinsky, MD, MPH,p Craig L. Leonardi, MD,q Jason Lichten, MD,m NehalN.Mehta,MD,MSCE,r Amy S. Paller, MD,s Sylvia L. Parra, MD,t Arun L. Pathy, MD,u Elizabeth A. Farley Prater, MD,v Reena N. Rupani, MD,e Michael Siegel, PhD,m BruceE.Strober,MD,PhD,w,x Emily B. Wong, MD,y Jashin J. Wu, MD,z Vidhya Hariharan, PhD,aa and Alan Menter, MD (Co-Chair)n Birmingham, Alabama; Detroit, Michigan; Atlanta, Georgia; San Francisco, Los Angeles, San Diego, and Irvine, California; New York, New York; Rochester, Minnesota; Philadelphia and Pittsburgh, Pennsylva- nia; Milwaukee, Wisconsin; Portland, Oregon; Dallas and San Antonio, Texas; Cleveland, Ohio; Boston, Massachusetts; St. Louis, Missouri; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Oklahoma City, Oklahoma; Farmington, Connecticut; and Waterloo, Ontario, Canada Psoriasis is a chronic inﬂammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population.
[Show full text]
Abbvie Allergan Acquisition
Creating a New Diversified Biopharmaceutical Company The Combination of AbbVie and Allergan Investor Presentation June 25, 2019 NO OFFER OR SOLICITATION This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this presentation is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The acquisition will be made solely by means of the Scheme Document (or, if applicable, the Takeover Offer document), which will contain the full terms and conditions of the acquisition, including details with respect to the AbbVie shareholder vote in respect of the acquisition. Any decision in respect of, or other response to, the acquisition, should be made only on the basis of the information contained in the Scheme Document. IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC In connection with the proposed Acquisition, Allergan will file with the Securities Exchange Commission (the “SEC”) a Proxy Statement, which will include the Scheme Document.
[Show full text]
[Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical
This document is scheduled to be published in the Federal Register on 06/21/2017 and available online at https://federalregister.gov/d/2017-12908, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-3203] Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 121 new drug applications (NDAs) and 161 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: The withdrawal is effective on [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. 2 Table 1 Application No.
[Show full text]
Annual Report on Annual Reports 2016
ANNUAL REPORT ON ANNUAL REPORTS 2016 TOP 400 ANNUAL REPORTS WHO RANKS WHERE? 100 ANNUALS IN BRIEF BEST REPORTING PRACTICES Company Value > Report Value Annual Report on Annual Reports 2016 Contents Report rating scale 3 Top 400 annual reports 4 Who ranks where? 25 From ABB to ZTE 100 annuals in brief 58 From Abbott to Yamaha How important is the annual report today? 92 Views from Cecilia Ketels, Kellie Friery, Renee Carter, David Robinson, Kaevan Gazdar, Elena Moskvina, Thomas Rosenmayr, Rob Stangroom, Andrey Kozhevnikov, Ana Santamarina, Katie Holcomb, Ananda Jagoda Best practices on key report attibutes 100 Strategy, message, investor information, risks, style, online… How we make it 121 How is your report doing? The report scan 127 The report rating panel 128 Robert Berick, Susan Blesener, Renee Carter, Vero Escarmelle, Helena Fournial, Kaevan Gazdar, Mike Guillaume, Pradip Seth, Eva Wolosiuk Making reports pay off 133 e.com – ReportWatch 135 2 Report rating scale A+ ééééé First-rate A éééé(é) Excellent A- éééé Very good B+ ééé(é) Sound B ééé Average B- éé(é) Uneven C+ éé Common C é(é) Substandard C- é Poor D (é) Uncompetitive 3 Top 400 annual reports AkzoNobel (No. 1) Electrolux (No. 2 ) SCA (No. 3) Volvo (No. 4) 4 Report rank Company Country Report rating Compare 1 AKZONOBEL Netherlands A+ DUPONT 2 ELECTROLUX Sweden A+ WHIRLPOOL 3 SCA Sweden A+ KIMBERLY-CLARK 4 VOLVO Sweden A+ DAIMLER 5 POTASHCORP Canada A+ AGRIUM 6 ATLAS COPCO Sweden A SANDVIK 7 STORA ENSO Finland A UPM 8 BOLIDEN Sweden A GLENCORE 9 WIENERBERGER Austria A BORAL 10
[Show full text]
Sales of $20.7 Billion Reflecting Growth of 1.9%, Operational Growth of 3.2
RESULTS HAVE BEEN UPDATED IN ACCORDANCE WITH THE FORM 8-K FILED ON OCTOBER 23, 2019 JOHNSON & JOHNSON REPORTS 2019 THIRD-QUARTER RESULTS: • Sales of $20.7 billion reflecting growth of 1.9%, operational growth of 3.2%* and adjusted operational growth of 5.2%* • EPS of $0.66 decreased (54.2)%; adjusted EPS of $2.12 increased 3.4%* • Company increasing Full Year Sales and EPS guidance due to strong performance New Brunswick, N.J. (October 23, 2019) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2019. “Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharmaceuticals and Medical Devices, as well as continued optimization in our Consumer business,” said Alex Gorsky, Chairman and Chief Executive Officer. “As we look ahead, we remain confident in the strength of our broad-based business model, which is fueled by our disciplined portfolio management, focus on transformational innovation and dedicated employees around the world who position us for success today and well into the future.” OVERALL FINANCIAL RESULTS: THIRD QUARTER ($ in Millions, except EPS) 2019 2018 % Change Reported Sales $ 20,729 $ 20,348 1.9% Net Earnings 1,753 3,934 (55.4) EPS (diluted) $ 0.66 $ 1.44 (54.2) Non-GAAP* THIRD QUARTER ($ in Millions, except EPS) 2019 2018 % Change Operational Sales1,2 3.2% Adjusted Operational Sales1,3 5.2 Adjusted Net Earnings1,4 5,672 5,590 1.5 Adjusted EPS (diluted)1,4 $ 2.12 $ 2.05 3.4 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures
[Show full text]
Abbott Abbvie ACE Pharmaceuticals Alcon Alfasigma ALK Abello
Abbott Eisai MSD Animal Health Abbvie Elanco Mundipharma Pharmaceuticals ACE Pharmaceuticals Eli Lilly Mylan Alcon Essity Mylan Healthcare Alfasigma Eurocept Nevro Medical ALK Abello Eurocept Pharmaceuticals Nobel Biocare Allergan EUSA Pharma Nordic Pharma AllweCare Medical Ferring Norgine Pharma Almirall Flen Health Novartis Pharma Amgen FMH Medical Novo Nordisk Amomed Pharma Focus Care Pharmaceuticals Olympus Amryt Pharmaceuticals Fresenius Kabi Otsuka Pharmaceuticals Amryt Research Fresenius Medical Care Paion Apceth Galapagos Biopharma Pentax Arega Medical Galderma Pfizer Arthrex GDM Philips Electronics Astellas Pharma GE Healthcare PIERRE FABRE AstraZeneca Gedeon Richter PIERRE FABRE SANTE AtriCure Genzyme Pro Care AveXis Getinge Recordati B.Braun Medical Gilead Sciences ResMed Bausch&Lomb OPS GlaxoSmithKline Roche Diabetes Care Baxter Goodlife Pharma Roche Diagnostics Bayer Grünenthal Roche Pharma Bayer Animal Health Guerbet Sandoz Becton Dickinson GW Pharma Sanofi Beldico Horus Pharma Sanquin Plasma Products Benu Direct HRA Pharma Santen Biogen IDB Holland Santhera Bio-Rad Laboratories Incyte Biosciences Sarepta Biotronik InSpine Seagen Bioventus Intercept Pharma Seqirus Bluebird Bio Ipsen Farmaceutica Servier Boehringer Ingelheim Janssen -Cilag Shire Boehringer Ingelheim Animal Health Janssen-Cilag (Actelion) Siemens Healthineers Boston Scientific Jazz Pharmaceuticals SkylineDX Bracco Imaging Johnson & Johnson Medical Smith & Nephew Bristol-Myers Squibb Khondrion SoBi (Swedish Orphan Biovitrum) Cablon Medical Kyowa Kirin Pharma
[Show full text]
Sample of Current Attendees
SAMPLE OF CURRENT ATTENDEES TITLE COMPANY Sr Mgr Global Meetings Mgmt Amgen Prin Tradeshow Spec Boston Scientific Events Mgr PR Medical Events Sr Buyer Pharma Ops ITA Group Travel Services Supv Grifols Asia Pacific Pte Ltd Compliance Specialist GCO Spend Jouney Lead Global Mtgs Travel Events UCB Category Project Specialist Roche Events & Travel Mgr Teva Brasil Mgr Event Mgmt Bayer Congress Mgr MediCongress Services Global Events Mgmt Sr Assoc Amgen Assoc Dir Congresses & Events MSD Internal Event Mgr Gilead Sourcing Mgr BMS Dir Sourcing Meeting Alliance Custoerm Srvs Meetings Mgr Eli Lilly & Company Sr Congress Mgr Novartis Pharmaceuticals Sourcing Mgr BCD Meetings & Events Sr Buyer Meetings & Incentives Worldwide Sourcing Mgr American Express GBT Acct Mgr Venue Sourcing Ashfield Meetings & Events Mtg Planner AbbVie Sr Sourcing Mgr CWT Dir Sourcing Planning Partners International Meetings Mgr ACOG Meeting Mgr Pfizer Canada Global Event Lead Astellas Meeting & Events Sanofi Events Specialist Cook Medical Meetings & Events Mgr Pfizer Spain Pfizer Spain Sr Mgr Hotel Procurement Meetings & Incentives WorldWide Inc Event Planner SFU BCcampus Mgr Global Strategic Mtg Mgmt Teva Pharmaceuticals Global Mtgs & Events Virtual Mtgs Specialist AstraZeneca Global Congress Strategy Lead MSD Assoc Dir Congresses & Events Alnylam Pharmaceuticals Event Planner AbbVie Institutional & Scientific Events Coordr Almirall Congress Mgr AO Spine Sr Meeting Planner Medtronic Mgr Global Mtgs Mgmt Alnylam Pharmaceuticals Meeting Planner AbbVie Global Audit Meetings
[Show full text]
Alcon-20-F-2020.Pdf
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring the shell company report __________ Commission file number: 001-31269 Alcon Inc. (Exact name of Registrant as specified in its charter) N/A (Translation of Registrant's name into English) Switzerland (Jurisdiction of incorporation or organization) Rue Louis-d'Affry 6, 1701 Fribourg, Switzerland (Address of principal executive office) Royce Bedward, Chemin de Blandonnet 8, 1214 Vernier, Geneva, Switzerland; Tel: +41 58 911 20 00; Fax +41 58 911 32 22 (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class Trading Symbol(s) Name of each exchange on which registered SIX Swiss Exchange Ordinary Shares, nominal value CHF 0.04 per share ALC New York Stock Exchange Securities registered or to be registered pursuant to Section 12(g) of the Act. None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.
[Show full text]
FDA Listing of Authorized Generics As of July 1, 2021
FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
[Show full text]
11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
[Show full text]